These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 21273704)

  • 21. Monitoring polyglutamine toxicity in yeast.
    Duennwald ML
    Methods; 2011 Mar; 53(3):232-7. PubMed ID: 21144902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neurodegeneration caused by polyglutamine expansion is regulated by P-glycoprotein in Drosophila melanogaster.
    Yadav S; Tapadia MG
    Genetics; 2013 Nov; 195(3):857-70. PubMed ID: 24037265
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neurotoxicity Pathways in Drosophila Models of the Polyglutamine Disorders.
    Krench M; Littleton JT
    Curr Top Dev Biol; 2017; 121():201-223. PubMed ID: 28057300
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of NF-κB in astrocytes is sufficient to delay neurodegeneration induced by proteotoxicity in neurons.
    Li YX; Sibon OCM; Dijkers PF
    J Neuroinflammation; 2018 Sep; 15(1):261. PubMed ID: 30205834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila.
    Gunawardena S; Her LS; Brusch RG; Laymon RA; Niesman IR; Gordesky-Gold B; Sintasath L; Bonini NM; Goldstein LS
    Neuron; 2003 Sep; 40(1):25-40. PubMed ID: 14527431
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analyzing the aggregation of polyglutamine-expansion proteins and its modulation by molecular chaperones.
    Kubota H; Kitamura A; Nagata K
    Methods; 2011 Mar; 53(3):267-74. PubMed ID: 21195182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glial cell lineage expression of mutant ataxin-1 and huntingtin induces developmental and late-onset neuronal pathologies in Drosophila models.
    Tamura T; Sone M; Yamashita M; Wanker EE; Okazawa H
    PLoS One; 2009; 4(1):e4262. PubMed ID: 19165334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polyglutamines stop traffic: axonal transport as a common target in neurodegenerative diseases.
    Feany MB; La Spada AR
    Neuron; 2003 Sep; 40(1):1-2. PubMed ID: 14527425
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RNA-binding protein hoip accelerates polyQ-induced neurodegeneration in Drosophila.
    Murata T; Suzuki E; Ito S; Sawatsubashi S; Zhao Y; Yamagata K; Tanabe M; Fujiyama S; Kimura S; Ueda T; Matsukawa H; Kouzmenko A; Furutani T; Kuranaga E; Miura M; Takeyama K; Kato S
    Biosci Biotechnol Biochem; 2008 Sep; 72(9):2255-61. PubMed ID: 18776683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Autophagy in polyglutamine disease: Imposing order on disorder or contributing to the chaos?
    Cortes CJ; La Spada AR
    Mol Cell Neurosci; 2015 May; 66(Pt A):53-61. PubMed ID: 25771431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proteome analysis of soluble nuclear proteins reveals that HMGB1/2 suppress genotoxic stress in polyglutamine diseases.
    Qi ML; Tagawa K; Enokido Y; Yoshimura N; Wada Y; Watase K; Ishiura S; Kanazawa I; Botas J; Saitoe M; Wanker EE; Okazawa H
    Nat Cell Biol; 2007 Apr; 9(4):402-14. PubMed ID: 17384639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Arginine is a disease modifier for polyQ disease models that stabilizes polyQ protein conformation.
    Minakawa EN; Popiel HA; Tada M; Takahashi T; Yamane H; Saitoh Y; Takahashi Y; Ozawa D; Takeda A; Takeuchi T; Okamoto Y; Yamamoto K; Suzuki M; Fujita H; Ito C; Yagihara H; Saito Y; Watase K; Adachi H; Katsuno M; Mochizuki H; Shiraki K; Sobue G; Toda T; Wada K; Onodera O; Nagai Y
    Brain; 2020 Jun; 143(6):1811-1825. PubMed ID: 32436573
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in Drosophila.
    Marsh JL; Walker H; Theisen H; Zhu YZ; Fielder T; Purcell J; Thompson LM
    Hum Mol Genet; 2000 Jan; 9(1):13-25. PubMed ID: 10587574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Isolation of gene sets affected specifically by polyglutamine expression: implication of the TOR signaling pathway in neurodegeneration.
    Nelson B; Nishimura S; Kanuka H; Kuranaga E; Inoue M; Hori G; Nakahara H; Miura M
    Cell Death Differ; 2005 Aug; 12(8):1115-23. PubMed ID: 15861189
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neurodegeneration: RNA turns number one suspect in polyglutamine diseases.
    Birman S
    Curr Biol; 2008 Aug; 18(15):R659-R661. PubMed ID: 18682207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RNA toxicity in polyglutamine disorders: concepts, models, and progress of research.
    Fiszer A; Krzyzosiak WJ
    J Mol Med (Berl); 2013 Jun; 91(6):683-91. PubMed ID: 23512265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polyglutamine and neurodegeneration: structural aspects.
    Masino L
    Protein Pept Lett; 2004 Jun; 11(3):239-48. PubMed ID: 15182225
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multi-domain misfolding: understanding the aggregation pathway of polyglutamine proteins.
    Saunders HM; Bottomley SP
    Protein Eng Des Sel; 2009 Aug; 22(8):447-51. PubMed ID: 19589877
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polyglutamine diseases: where does toxicity come from? what is toxicity? where are we going?
    Takahashi T; Katada S; Onodera O
    J Mol Cell Biol; 2010 Aug; 2(4):180-91. PubMed ID: 20410236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila.
    Steffan JS; Bodai L; Pallos J; Poelman M; McCampbell A; Apostol BL; Kazantsev A; Schmidt E; Zhu YZ; Greenwald M; Kurokawa R; Housman DE; Jackson GR; Marsh JL; Thompson LM
    Nature; 2001 Oct; 413(6857):739-43. PubMed ID: 11607033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.